Previously, we demonstrated that the proteasome inhibitor bortezomib was effective in high-MAP17-expressing tumors from various origins, including sarcomas, breast cancer, and lung cancer tumors [13,17,18,19]. This evidence concerns the gene PDZK1IP1 and sarcoma.